240 related articles for article (PubMed ID: 37024412)
1. Real-life safety profile of mRNA vaccines for COVID-19: An analysis of VAERS database.
Santi Laurini G; Montanaro N; Broccoli M; Bonaldo G; Motola D
Vaccine; 2023 May; 41(18):2879-2886. PubMed ID: 37024412
[TBL] [Abstract][Full Text] [Related]
2. Facial nerve palsy following the administration of COVID-19 mRNA vaccines: analysis of a self-reporting database.
Sato K; Mano T; Niimi Y; Toda T; Iwata A; Iwatsubo T
Int J Infect Dis; 2021 Oct; 111():310-312. PubMed ID: 34492394
[TBL] [Abstract][Full Text] [Related]
3. Safety monitoring of bivalent mRNA COVID-19 vaccine among pregnant persons in the vaccine adverse event reporting System - United States, September 1, 2022 - March 31, 2023.
Moro PL; Carlock G; Fifadara N; Habenicht T; Zhang B; Strid P; Marquez P
Vaccine; 2024 Apr; 42(9):2380-2384. PubMed ID: 38462432
[TBL] [Abstract][Full Text] [Related]
4. Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021.
Oster ME; Shay DK; Su JR; Gee J; Creech CB; Broder KR; Edwards K; Soslow JH; Dendy JM; Schlaudecker E; Lang SM; Barnett ED; Ruberg FL; Smith MJ; Campbell MJ; Lopes RD; Sperling LS; Baumblatt JA; Thompson DL; Marquez PL; Strid P; Woo J; Pugsley R; Reagan-Steiner S; DeStefano F; Shimabukuro TT
JAMA; 2022 Jan; 327(4):331-340. PubMed ID: 35076665
[TBL] [Abstract][Full Text] [Related]
5. Curbing COVID-19 Vaccine Hesitancy from a Dermatological Standpoint: Analysis of Cutaneous Reactions in the Vaccine Adverse Event Reporting System (VAERS) Database.
Falotico JM; Desai AD; Shah A; Ricardo JW; Lipner SR
Am J Clin Dermatol; 2022 Sep; 23(5):729-737. PubMed ID: 35931925
[TBL] [Abstract][Full Text] [Related]
6. Vaccine-Associated Uveitis after COVID-19 Vaccination: Vaccine Adverse Event Reporting System Database Analysis.
Singh RB; Parmar UPS; Kahale F; Agarwal A; Tsui E
Ophthalmology; 2023 Feb; 130(2):179-186. PubMed ID: 36055601
[TBL] [Abstract][Full Text] [Related]
7. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5-11 Years - United States, October 12-January 1, 2023.
Hause AM; Marquez P; Zhang B; Su JR; Myers TR; Gee J; Panchanathan SS; Thompson D; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2023 Jan; 72(2):39-43. PubMed ID: 36634021
[TBL] [Abstract][Full Text] [Related]
8. Safety of COVID-19 vaccines in pregnancy: a VAERS based analysis.
Santi Laurini G; Montanaro N; Motola D
Eur J Clin Pharmacol; 2023 May; 79(5):657-661. PubMed ID: 36961579
[TBL] [Abstract][Full Text] [Related]
9. Capillary leak syndrome following COVID-19 vaccination: Data from the European pharmacovigilance database Eudravigilance.
Ruggiero R; Balzano N; Di Napoli R; Mascolo A; Berrino PM; Rafaniello C; Sportiello L; Rossi F; Capuano A
Front Immunol; 2022; 13():956825. PubMed ID: 36177033
[TBL] [Abstract][Full Text] [Related]
10. Myocarditis and/or pericarditis risk after mRNA COVID-19 vaccination: A Canadian head to head comparison of BNT162b2 and mRNA-1273 vaccines.
Abraham N; Spruin S; Rossi T; Fireman B; Zafack J; Blaser C; Shaw A; Hutchings K; Ogunnaike-Cooke S
Vaccine; 2022 Jul; 40(32):4663-4671. PubMed ID: 35750537
[TBL] [Abstract][Full Text] [Related]
11. Safety of Booster Doses of Coronavirus Disease 2019 (COVID-19) Vaccine in Pregnancy in the Vaccine Adverse Event Reporting System.
Moro PL; Olson CK; Zhang B; Marquez P; Strid P
Obstet Gynecol; 2022 Sep; 140(3):421-427. PubMed ID: 35926203
[TBL] [Abstract][Full Text] [Related]
12. Comparative safety of mRNA COVID-19 vaccines to influenza vaccines: A pharmacovigilance analysis using WHO international database.
Kim MS; Jung SY; Ahn JG; Park SJ; Shoenfeld Y; Kronbichler A; Koyanagi A; Dragioti E; Tizaoui K; Hong SH; Jacob L; Salem JE; Yon DK; Lee SW; Ogino S; Kim H; Kim JH; Excler JL; Marks F; Clemens JD; Eisenhut M; Barnett Y; Butler L; Ilie CP; Shin EC; Il Shin J; Smith L
J Med Virol; 2022 Mar; 94(3):1085-1095. PubMed ID: 34709664
[TBL] [Abstract][Full Text] [Related]
13. Comparative safety profile of bivalent and original COVID-19 mRNA vaccines regarding myocarditis/pericarditis: A pharmacovigilance study.
Chen C; Chen C; Cao L; Fang J; Xiao J
Int Immunopharmacol; 2024 May; 133():112022. PubMed ID: 38615382
[TBL] [Abstract][Full Text] [Related]
14. Post-authorization surveillance of adverse events following COVID-19 vaccines in pregnant persons in the vaccine adverse event reporting system (VAERS), December 2020 - October 2021.
Moro PL; Olson CK; Clark E; Marquez P; Strid P; Ellington S; Zhang B; Mba-Jonas A; Alimchandani M; Cragan J; Moore C
Vaccine; 2022 May; 40(24):3389-3394. PubMed ID: 35489985
[TBL] [Abstract][Full Text] [Related]
15. Risk of myocarditis after three doses of COVID-19 mRNA vaccines in the United States, 2020-2022: A self-controlled case series study.
Lai D; Lim D; Lu J; Wang H; Huang T; Zhang YD
J Evid Based Med; 2024 Mar; 17(1):65-77. PubMed ID: 38494781
[TBL] [Abstract][Full Text] [Related]
16. Comparative assessment of myocarditis and pericarditis reporting rates related to mRNA COVID-19 vaccines in Europe and the United States.
Hatziantoniou S; Anastassopoulou C; Lazaros G; Vasileiou K; Tsioufis C; Tsakris A
Expert Rev Vaccines; 2022 Nov; 21(11):1691-1696. PubMed ID: 35815358
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada.
Buchan SA; Seo CY; Johnson C; Alley S; Kwong JC; Nasreen S; Calzavara A; Lu D; Harris TM; Yu K; Wilson SE
JAMA Netw Open; 2022 Jun; 5(6):e2218505. PubMed ID: 35749115
[TBL] [Abstract][Full Text] [Related]
18. Safety Monitoring of Pfizer-BioNTech COVID-19 Vaccine Booster Doses Among Children Aged 5-11 Years - United States, May 17-July 31, 2022.
Hause AM; Baggs J; Marquez P; Myers TR; Su JR; Hugueley B; Thompson D; Gee J; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2022 Aug; 71(33):1047-1051. PubMed ID: 35980875
[TBL] [Abstract][Full Text] [Related]
19. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥12 Years - United States, August 31-October 23, 2022.
Hause AM; Marquez P; Zhang B; Myers TR; Gee J; Su JR; Blanc PG; Thomas A; Thompson D; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2022 Nov; 71(44):1401-1406. PubMed ID: 36327162
[TBL] [Abstract][Full Text] [Related]
20. First Month of COVID-19 Vaccine Safety Monitoring - United States, December 14, 2020-January 13, 2021.
Gee J; Marquez P; Su J; Calvert GM; Liu R; Myers T; Nair N; Martin S; Clark T; Markowitz L; Lindsey N; Zhang B; Licata C; Jazwa A; Sotir M; Shimabukuro T
MMWR Morb Mortal Wkly Rep; 2021 Feb; 70(8):283-288. PubMed ID: 33630816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
